This molecule has also tested in combination with stereotactic body radiotherapy to promote T-cell antitumor immunity, showing an anti-HCC effect featured by an increase in the CD8 PD1+ TIGIT+ population [121]. Here, TIGIT is linked to hepatocellular carcinoma.